Bone Morphogenetic Protein-7 and disease progression in renal amyloidosis patients

Figures & data

Figure 1. Flow-chart design of the study.

Table 1. Baseline demographic characteristics and laboratory data of the entire study population (n = 93).

Sex (female/male)	48/45 (52%/48%)
Age (years)	37 ± 12.26
Creatinine (mg/dL)	1.17 ± 0.5
eGFR (mL/min)	68.9 ± 24.6
Hemoglobin (g/dL)	13.12 ± 1.74
iPTH (pg/mL)	93.77 ± 80.67
Uric acid (mg/dL)	4.58 ± 1.66
CRP (mg/dL)	0.72 ± 1.65
Total Cholesterol (mg/dL)	211.5 ± 66.18
Proteinuria (mg/day)	3071 (32–17,700)
BMP7 level (pg/mL)	468 ± 11.4
Follow-up period (months)	24.4 ± 2.7

eGFR: estimated glomerular filtration rate, iPTH: intact parathyroidhormone, CRP: c-reactive protein, BMP 7: Bone morphogenetic protein 7.

Figure 2. Changes in estimated glomerular filtration rates of the study groups.

Table 2. Baseline and follow-up values of the groups in terms of serum BMP7, creatinine and eGFR.

	Group I (n = 46)	Group II (n = 47)	p
BMP7 (pg/mL)
Baseline	436 ± 66.6	420 ± 92.2	0.48
End of follow-up	522 ± 34.7	464 ± 89.4	0.02
Serum creatinin (mg/dL)
Baseline	1.24 ± 0.39	1.11 ± 0.61	0.56
6th month	1.56 ± 0.36	1.18 ± 0.7	0.13
12nd month	1.68 ± 0.42	1.1 ± 0.74	0.04
18th month	1.7 ± 0.37	1.15 ± 0.78	0.06
24th month	1.79 ± 0.33	1.16 ± 0.7	0.019
eGFR
Baseline	62.5 ± 22.64	75.4 ± 26.03	0.25
6th month	44.8 ± 6.66	72.1 ± 26.34	0.005
12nd month	41.6 ± 6.56	82.04 ± 26.54	<0.001
18th month	40.6 ± 4.99	83.97 ± 32.48	0.001
24th month	38 ± 4.57	79.19 ± 24.11	<0.001